Acerand Therapeutics Updates the Phase I/II Study of ACE-106 (ACE-86225106), a highly selective and Potentially Best-in-class PARP1 Inhibitor, in Advanced Solid Tumors

Acerand Therapeutics gets the greenlight by CDE for the clinical study of ACE-232 (a novel CYP11A1 inhibitor ) in China

Acerand Therapeutics Initiates First-in-Human Phase 1 Clinical Trial of ACE-232, a Novel CYP11A1 Inhibitor for Advanced Prostate Cancer

Acerand Therapeutics Announces Preliminary Clinical Data of a Novel, Selective PARP1 Inhibitor ACE-86225106 to Be Presented at the 2025 ASCO Meeting

Acerand Announces Promising ACE-232 Preclinical Data to Be Presented at the 2025 AACR Meeting

Acerand Therapeutics announced the approval of their novel CYP11A1 inhibitor ACE-232 by FDA for clinic investigations

Acerand Therapeutics completes First patient enrollment in the Phase 1/2 clinical trial of a selective PARP1 inhibitor

Acerand Therapeutics announced the approval of their next generation PARP1 selective inhibitor ACE-86225106 by CDE for clinic investigations

Repost | Hui Hui Yao Ka Interviews Acerand's Executive Director of CADD, Hongbin Yuan: Embracing a CADD Mindset in Drug Discovery

Research Collaboration between XtalPi Inc and Acerand Therapeutics to develop potential novel anti-cancer therapies using High-precision Physics-based model and Machine Learning.